This trial is evaluating whether [11C]UCB-J radiotracer will improve 1 primary outcome in patients with Schizophrenia. Measurement will happen over the course of 120 minutes (scan duration).
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. [11C]UCB-J Radiotracer is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
Although some patients may experience some improvement, there is no absolute proof that schizophrenia can be cured. However, significant advances are being made in understanding neural mechanisms of psychosis.
There are a variety of factors affecting annual incidence of schizophrenia. One is the age at which the first psychosis occurs. A later age at onset has been associated with a higher rate of incidence, but this effect appears to operate through a mechanism other than the natural course of schizophrenia. Other factors may influence the incidence of schizophrenic psychosis through some effect on the vulnerability to the illness, such as genetic susceptibility or neurodevelopmental insult.
Schizophrenia is sometimes defined as a specific mental disorder that is characterised by profound and unusual symptoms accompanied by disorganisation of thought, speech, and behaviour, which are not attributable to the direct effects of a drug or physical disease. When the presentation resembles some other mental disorder, such as the mood disorders depression and anxiety, the use of other descriptive terms such as psychotic, disordered, or bizarre is more appropriate.\n
This review indicates that pharmacological treatments prevail, with multiple lines of medication for each type of disorder. The main pharmacological treatment for schizophrenia is antipsychotic medication.
The signs of schizophrenia are varied and nonspecific. The symptoms of schizophrenia have a wide range in presentation. Schizophrenia can be associated with a variety of physical signs such as skin changes and lymph node enlargement. The signs of schizophrenia can be divided into nonspecific and specific signs. The nonspecific manifestations are associated with many other physical signs and complaints of patients with schizophrenia. The specific signs are associated with certain physical disorders.
There is no single, single etiological cause of schizophrenia, and the development of schizophrenia is probably multifactorial. However, common factors such as environmental factors, infection, genetics, and the immune system may play important roles in the development of schizophrenia, and the genetic component of schizophrenia is significant.
Recent research into the underlying causes of schizophrenia continues to provide new information into this complex phenomenon. The potential to clarify pathogenic mechanisms in schizophrenia is very real. It is estimated that a new generation of anti-psychotics with potent and selective pharmacological properties will soon be available to patients, a potential dramatic breakthrough for people suffering from this disease.
The primary cause of schizophrenia which is in essence atypical of schizophrenia may be traced into a number of things including the influence of parenting, the influence of sex/gender on the course of the illness, one's genetic makeup, epigenetic modifications and the influence of viruses.
[11C]ucb-j PET provides a powerful tool to assess BZD binding. We will show that SNC81-3 binds preferentially to high-affinity BZD receptors and that SNC81-3 may be of practical value for defining high- and low-affinity binding sites in the human brain.
Although there are multiple treatment options available to patients with schizophrenia, there is no single treatment found to be the right and best approach; rather, each patient needs unique treatment based on the signs and symptoms, age, and any other individual or contextual factors. New treatments may arise for the treatment of schizophrenia. We are only beginning to understand its complexity and the many causes.
As families are regarded as being in the best position to prevent the occurrence of schizophrenic disorders, the answer is a big, yes, so we need to start looking for more genetic factors that are not currently being explored. One area to look at is the role that family stressors and early experiences can play in the development of schizophrenia. The influence of specific family factors, such as family discord, is another issue that merits scrutiny.
The combination of [11C]ucb-j with cognitive behavioral or pharmacological treatment may provide some advantages over cognitive-only treatment or monotherapy (e.g., an advantage in symptom severity or quality of life).